

August 16, 2010



# Pressure BioSciences, Inc. to Discuss Second Quarter 2010 Financial Results and Provide Business Update

SOUTH EASTON, Mass., Aug. 16, 2010 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2010 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone or through a live web-cast. The teleconference and web-cast information is provided below:

Date: Tuesday, August 17, 2010  
Time: 4:30 p.m. Eastern Daylight Savings Time (EDST)

To attend this teleconference via web-cast, please go to the Company's website:  
[www.pressurebiosciences.com](http://www.pressurebiosciences.com)

To attend this teleconference via telephone: Dial-in: (866) 834-4534

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call ends through September 30, 2010, and will be accessible through the Company's website.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development and sale of instruments and consumables based on a novel, enabling platform called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

CONTACT: Pressure BioSciences, Inc.  
Investor Contacts:  
Richard T. Schumacher, President & CEO  
Joseph Damasio, Jr., Controller  
508-230-1828